Lahjavida
Biotechnology company developing a modular small-molecule Dye–Drug Conjugate (DDC) platform that uses tumor-targeting near-infrared dyes, cleavable linkers, and clinically validated cytotoxic payloads to concentrate therapeutics in tumors while reducing systemic toxicity. The company is advancing multiple preclinical programs toward IND readiness, emphasizing scalable small-molecule CMC, theranostic imaging, and partnership opportunities.
Industries
Nr. of Employees
small (1-50)
Lahjavida
Colorado Springs, Colorado, United States, North America
Patents
Products
Lead DDC candidate (preclinical)
A lead dye–linker–payload conjugate undergoing preclinical optimization for tumor-selective uptake, payload release, and IND-enabling safety studies.
Pipeline of DDC Constructs (DDC1–DDC10)
A portfolio of DDC constructs varying by dye, linker, and payload (including topoisomerase inhibitors, microtubule inhibitors, anthracyclines, and combination payload constructs) to address multiple solid tumors.
Dye-Drug Conjugates (DDCs)
A first-in-class platform for tumor-selective small-molecule delivery designed to concentrate potent cancer therapies in tumors while sparing healthy tissue, aiming to improve precision and tolerability by reducing systemic toxicity.
First-in-Class Dye-Drug Conjugate (DDC) Platform
A new class of small-molecule Dye-Drug Conjugates designed to concentrate potent cancer therapies in tumors while sparing healthy tissue, aiming to improve precision and tolerability by reducing systemic toxicity.
DDC1
A dye-drug conjugate using Dye 1, Linker #1, and SN38 payload, designed for tumor-selective uptake and payload release in solid tumor oncology.
DDC7
A dye-drug conjugate consisting of Dye 1, Linker #5, and the payload Doxorubicin, an anthracycline that intercalates into DNA and inhibits topoisomerase II causing DNA breaks and cytotoxicity.
Lead DDC candidate (preclinical)
A lead dye–linker–payload conjugate undergoing preclinical optimization for tumor-selective uptake, payload release, and IND-enabling safety studies.
Pipeline of DDC Constructs (DDC1–DDC10)
A portfolio of DDC constructs varying by dye, linker, and payload (including topoisomerase inhibitors, microtubule inhibitors, anthracyclines, and combination payload constructs) to address multiple solid tumors.
Dye-Drug Conjugates (DDCs)
A first-in-class platform for tumor-selective small-molecule delivery designed to concentrate potent cancer therapies in tumors while sparing healthy tissue, aiming to improve precision and tolerability by reducing systemic toxicity.
First-in-Class Dye-Drug Conjugate (DDC) Platform
A new class of small-molecule Dye-Drug Conjugates designed to concentrate potent cancer therapies in tumors while sparing healthy tissue, aiming to improve precision and tolerability by reducing systemic toxicity.
DDC1
A dye-drug conjugate using Dye 1, Linker #1, and SN38 payload, designed for tumor-selective uptake and payload release in solid tumor oncology.
DDC7
A dye-drug conjugate consisting of Dye 1, Linker #5, and the payload Doxorubicin, an anthracycline that intercalates into DNA and inhibits topoisomerase II causing DNA breaks and cytotoxicity.
Services
Advancing modular dye–linker–payload programs through preclinical optimization, efficacy and safety testing, and IND-enabling activities.
GMP process transfer and documentation to support clinical manufacturing of small-molecule conjugates.
Advancing modular dye–linker–payload programs through preclinical optimization, efficacy and safety testing, and IND-enabling activities.
GMP process transfer and documentation to support clinical manufacturing of small-molecule conjugates.
Expertise Areas
- Small-molecule targeted oncology therapeutics
- Tumor-targeting biology (transporter-mediated uptake)
- Preclinical efficacy and safety assessment
- CMC for synthetic small molecules
Key Technologies
- Heptamethine carbocyanine near-infrared (NIR) dyes
- Valine–citrulline (Val–Cit) cleavable linkers
- Small-molecule conjugation chemistry
- LC-MS / LC-MS/MS quantitation
News & Updates
Presentation of preclinical data demonstrating tumor-targeting capability, sustained tumor suppression in xenograft models, and favorable safety characteristics for the DDC platform.
Announcement of a new fractional Chief Operating Officer to lead operations, clinical, regulatory, and commercial strategy as the company advances its DDC platform.
Acceptance of an abstract describing the DDC platform for presentation at the AACR Annual Meeting 2026.
Presentation of preclinical data demonstrating tumor-targeting capability, sustained tumor suppression in xenograft models, and favorable safety characteristics for the DDC platform.
Announcement of a new fractional Chief Operating Officer to lead operations, clinical, regulatory, and commercial strategy as the company advances its DDC platform.
Acceptance of an abstract describing the DDC platform for presentation at the AACR Annual Meeting 2026.